Research and technical health institutes' constituency

in page functions

The research and technical health institutes' constituency has one seat on the Gavi Board

The Research and technical health institutes' constituency is currently represented by the Aga Khan University and the University of Maryland School of Medicine / Center for Vaccine Development (CVD):

Zulfiqar A. Bhutta (Representative) and Samba O. Sow (Alternate) represent these institutes:

Agence de Médecine Préventive (AMP) 

Armauer Hansen Research Inst. (AHRI) 

US Centers for Disease Control and Prevention 

Centre for International Health, University of Bergen 

Emory University 

Euro Health Group 

Global Immunization Division, US CDC 

Harvard School of Public Health 

Health Systems Research Institute 

Institut Pasteur of Dakar 

Institut Pasteur 

Institute for Health Metrics and Evaluation 

Institution Panorama

Instituto de Investigación Nutricional 

Johns Hopkins University 

Karolinska Institute 

London School of Hygiene and Tropical Medicine 

Medicines for Malaria 

Medical Research Council Laboratory 

National Institute for
Biological Standards and Control

National Institute of Health 

National Institute of Infectious Diseases 

National Institute of Vaccines & Biological Substances 

PNG Institute of Medical Research 

Stanford University 

Statens Serum Institute 

Trinity college Dublin 

University of Gothenburg 

University of Maryland School of Medicine 

University of Melbourne 

University of Nairobi 

University of Witwatersrand 

Nominations process 

There is a Secretariat-facilitated process in place, where the Secretariat:

- works with the Board member and the constituency to develop the terms of reference for the seat;

- posts a call for nominations on the Gavi website, encouraging female candidates to apply;

- sends a call for nominations directly to research and technical health institutes within the Vaccine Alliance contact list, encouraging female candidates to apply;

- forms a shortlist to be interviewed by the subcommittee.

The subcommittee voices its preference for a Board member and alternate at the next Board meeting.

More on this topic

US$ 80-100 billion

Investing in Gavi’s 2016-2020 strategy has the potential to deliver US$ 80-100 billion in costs averted related to illness, such as productivity loss due to death/disability, treatment costs, caretaker productivity loss and transport costs.

Stack M et al. Estimated economic benefits during Decade of Vaccines, Health Affairs 2011

More facts...

close icon

modal window here